Mark W. Lundy

2.6k total citations
44 papers, 2.1k citations indexed

About

Mark W. Lundy is a scholar working on Oncology, Orthopedics and Sports Medicine and Molecular Biology. According to data from OpenAlex, Mark W. Lundy has authored 44 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Oncology, 27 papers in Orthopedics and Sports Medicine and 16 papers in Molecular Biology. Recurrent topics in Mark W. Lundy's work include Bone health and treatments (27 papers), Bone health and osteoporosis research (23 papers) and Bone Metabolism and Diseases (14 papers). Mark W. Lundy is often cited by papers focused on Bone health and treatments (27 papers), Bone health and osteoporosis research (23 papers) and Bone Metabolism and Diseases (14 papers). Mark W. Lundy collaborates with scholars based in United States, United Kingdom and France. Mark W. Lundy's co-authors include Frank H. Ebetino, R.G.G. Russell, David J. Baylink, Charles E. McKenna, Shuting Sun, James E. Dunford, Jon E. Wergedal, Michael J. Rogers, James T. Triffitt and B. A. Kashemirov and has published in prestigious journals such as Cancer Research, Annals of the New York Academy of Sciences and Journal of Medicinal Chemistry.

In The Last Decade

Mark W. Lundy

42 papers receiving 2.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mark W. Lundy United States 23 1.1k 976 789 302 248 44 2.1k
Abraham Schneider United States 28 1.4k 1.3× 464 0.5× 1.1k 1.3× 192 0.6× 303 1.2× 73 3.3k
Julie C. Frith United Kingdom 13 2.3k 2.1× 1.1k 1.2× 928 1.2× 659 2.2× 320 1.3× 17 2.9k
R. Graham United Kingdom 15 913 0.9× 458 0.5× 454 0.6× 237 0.8× 161 0.6× 30 1.8k
Pierrick G.J. Fournier United States 26 1.7k 1.6× 408 0.4× 1.1k 1.4× 429 1.4× 171 0.7× 37 2.8k
Harald L. Guenther Switzerland 23 795 0.7× 469 0.5× 642 0.8× 153 0.5× 156 0.6× 34 1.6k
Steven P. Luckman United Kingdom 12 3.4k 3.2× 1.8k 1.8× 1.4k 1.8× 920 3.0× 450 1.8× 16 4.3k
Cedric Minkin United States 23 1.1k 1.0× 422 0.4× 1.3k 1.7× 86 0.3× 235 0.9× 42 2.4k
Satoshi Yokose Japan 19 371 0.3× 184 0.2× 717 0.9× 111 0.4× 119 0.5× 67 1.4k
Monica Marra Italy 25 653 0.6× 318 0.3× 462 0.6× 252 0.8× 804 3.2× 48 2.3k
T. Sasaki Japan 20 809 0.8× 426 0.4× 1.4k 1.7× 73 0.2× 226 0.9× 54 2.2k

Countries citing papers authored by Mark W. Lundy

Since Specialization
Citations

This map shows the geographic impact of Mark W. Lundy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark W. Lundy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark W. Lundy more than expected).

Fields of papers citing papers by Mark W. Lundy

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark W. Lundy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark W. Lundy. The network helps show where Mark W. Lundy may publish in the future.

Co-authorship network of co-authors of Mark W. Lundy

This figure shows the co-authorship network connecting the top 25 collaborators of Mark W. Lundy. A scholar is included among the top collaborators of Mark W. Lundy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark W. Lundy. Mark W. Lundy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hokugo, Akishige, Shuting Sun, Yujie Sun, et al.. (2019). Rescue bisphosphonate treatment of alveolar bone improves extraction socket healing and reduces osteonecrosis in zoledronate-treated mice. Bone. 123. 115–128. 28 indexed citations
2.
Lawson, Michelle A., Frank H. Ebetino, Artur Mazur, et al.. (2017). The Pharmacological Profile of a Novel Highly Potent Bisphosphonate, OX14 (1-Fluoro-2-(Imidazo-[1,2-α]Pyridin-3-yl)-Ethyl-Bisphosphonate). Journal of Bone and Mineral Research. 32(9). 1860–1869. 19 indexed citations
3.
Lundy, Mark W., Shuxin Sun, Xiaonan Duan, et al.. (2014). Skeletal Retention and Urinary Excretion of Nitrogen-Containing Bisphosphonates Including Fluorescently-labeled Bisphosphonates in Rats.. Journal of Bone and Mineral Research. 29. 1 indexed citations
4.
Recker, R. R., Louis‐Georges Ste‐Marie, Pascale Chavassieux, Michael R. McClung, & Mark W. Lundy. (2014). Bone safety with risedronate: histomorphometric studies at different dose levels and exposure. Osteoporosis International. 26(1). 327–337. 8 indexed citations
5.
Turek, John, Frank H. Ebetino, Mark W. Lundy, et al.. (2012). Bisphosphonate Binding Affinity Affects Drug Distribution in Both Intracortical and Trabecular Bone of Rabbits. Calcified Tissue International. 90(3). 202–210. 33 indexed citations
6.
Ebetino, Frank H., Anne‐Marie L. Hogan, Shuting Sun, et al.. (2011). The relationship between the chemistry and biological activity of the bisphosphonates. Bone. 49(1). 20–33. 308 indexed citations
7.
Roelofs, Anke J., Shuting Sun, K. M. Błażewska, et al.. (2011). Influence of bone affinity on the skeletal distribution of fluorescently labeled bisphosphonates in vivo. Journal of Bone and Mineral Research. 27(4). 835–847. 82 indexed citations
8.
Roelofs, Anke J., Fraser P. Coxon, Frank H. Ebetino, et al.. (2009). Fluorescent risedronate analogues reveal bisphosphonate uptake by bone marrow monocytes and localization around osteocytes in vivo. Journal of Bone and Mineral Research. 25(3). 606–616. 137 indexed citations
9.
Roelofs, Anke J., A. Boyde, Mark W. Lundy, et al.. (2009). Bone mineral affinity influences the distribution of a bisphosphonate and a lower affinity analogue in vivo. Bone. 44. S430–S431. 2 indexed citations
10.
Fournier, Pierrick G.J., Florence Daubiné, Mark W. Lundy, et al.. (2008). Lowering Bone Mineral Affinity of Bisphosphonates as a Therapeutic Strategy to Optimize Skeletal Tumor Growth Inhibition In vivo. Cancer Research. 68(21). 8945–8953. 36 indexed citations
11.
Lundy, Mark W., Frank H. Ebetino, Zhidao Xia, et al.. (2007). Bisphosphonate affinity to hydroxyapatite and farnesyl pyrophosphate inhibitory potency, together, drive in vivo efficacy. Oxford University Research Archive (ORA) (University of Oxford). 4 indexed citations
12.
Yao, Wei, et al.. (2007). Rolipram, a phosphodiesterase 4 inhibitor, prevented cancellous and cortical bone loss by inhibiting endosteal bone resorption and maintaining the elevated periosteal bone formation in adult ovariectomized rats.. PubMed. 7(2). 119–30. 26 indexed citations
13.
Borah, Babul, Gary J. Gross, Thomas E. Dufresne, et al.. (2001). Three‐dimensional microimaging (MRμI and μCT), finite element modeling, and rapid prototyping provide unique insights into bone architecture in osteoporosis. The Anatomical Record. 265(2). 101–110. 166 indexed citations
14.
Lundy, Mark W., M. Stauffer, J. E. Wergedal, et al.. (1995). Histomorphometric analysis of iliac crest bone biopsies in placebo-treated versus fluoride-treated subjects. Osteoporosis International. 5(2). 115–129. 49 indexed citations
15.
Turner, A. Simon, et al.. (1995). Changes in bone mineral density and bone-specific alkaline phosphatase in ovariectomized ewes. Bone. 17(4). S395–S402. 85 indexed citations
16.
Lundy, Mark W., et al.. (1991). Growth Factor-Induced Proliferation of Osteoblasts Measured by Bromodeoxyuridine Immunocytochemistry. Growth Factors. 4(4). 257–264. 22 indexed citations
17.
Lundy, Mark W., et al.. (1989). The effect of prolonged fluoride therapy for osteoporosis: Bone composition and histology. Bone. 10(5). 321–327. 29 indexed citations
18.
Engström, Christian, John C. Jennings, Mark W. Lundy, & David J. Baylink. (1988). Effect of bone matrix‐derived growth factors on skull and tibia in the growing rat. Journal of Oral Pathology and Medicine. 17(7). 334–340. 7 indexed citations
19.
Lundy, Mark W., K.‐H. William Lau, Harry C. Blair, & David J. Baylink. (1988). Chick osteoblasts contain fluoride-sensitive acid phosphatase activity.. Journal of Histochemistry & Cytochemistry. 36(9). 1175–1180. 23 indexed citations
20.
Lundy, Mark W., Jonathan Farley, & David J. Baylink. (1986). Characterization of a rapidly responding animal model for fluoride-stimulated bone formation. Bone. 7(4). 289–293. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Abraham Schneider Breakdown of academic impact, for papers by Julie C. Frith Breakdown of academic impact, for papers by R. Graham Breakdown of academic impact, for papers by Pierrick G.J. Fournier Breakdown of academic impact, for papers by Harald L. Guenther Breakdown of academic impact, for papers by Steven P. Luckman Breakdown of academic impact, for papers by Cedric Minkin Breakdown of academic impact, for papers by Satoshi Yokose Breakdown of academic impact, for papers by Monica Marra Breakdown of academic impact, for papers by T. Sasaki
Rankless by CCL
2026